These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 11920601

  • 1. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
    Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G.
    Int J Cancer; 2002 Mar 20; 98(3):463-9. PubMed ID: 11920601
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2001 May 20; 7(5):1459-65. PubMed ID: 11350918
    [Abstract] [Full Text] [Related]

  • 3. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
    Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F.
    Clin Cancer Res; 2002 Oct 20; 8(10):3250-8. PubMed ID: 12374696
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N, Nishio K.
    Int J Cancer; 2002 Mar 10; 98(2):310-5. PubMed ID: 11857424
    [Abstract] [Full Text] [Related]

  • 5. Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
    Takabatake D, Fujita T, Shien T, Kawasaki K, Taira N, Yoshitomi S, Takahashi H, Ishibe Y, Ogasawara Y, Doihara H.
    Int J Cancer; 2007 Jan 01; 120(1):181-8. PubMed ID: 17036319
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 7. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2004 Jan 15; 10(2):784-93. PubMed ID: 14760102
    [Abstract] [Full Text] [Related]

  • 8. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 15; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 9. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
    Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, Sugiura T, Takahashi T, Hida T.
    Lung Cancer; 2003 Oct 15; 42(1):35-41. PubMed ID: 14512185
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG.
    Clin Cancer Res; 2000 Dec 15; 6(12):4885-92. PubMed ID: 11156248
    [Abstract] [Full Text] [Related]

  • 11. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
    Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R.
    Clin Cancer Res; 2004 Jan 15; 10(2):658-67. PubMed ID: 14760089
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
    Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Viganò L, Fumagalli M, Ménard S, Gianni L.
    J Cell Physiol; 2004 Feb 15; 198(2):259-68. PubMed ID: 14603528
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, Tortora G.
    Clin Cancer Res; 2000 May 15; 6(5):2053-63. PubMed ID: 10815932
    [Abstract] [Full Text] [Related]

  • 14. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G, Caputo R, Damiano V, Caputo R, Troiani T, Veneziani BM, De Placido S, Bianco AR, Zangemeister-Wittke U, Ciardiello F.
    Clin Cancer Res; 2003 Feb 15; 9(2):866-71. PubMed ID: 12576461
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G.
    Clin Cancer Res; 2003 Apr 15; 9(4):1546-56. PubMed ID: 12684431
    [Abstract] [Full Text] [Related]

  • 16. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
    Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.
    J Natl Cancer Inst; 2003 Dec 17; 95(24):1825-33. PubMed ID: 14679152
    [Abstract] [Full Text] [Related]

  • 17. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
    Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M.
    Clin Cancer Res; 2004 Jan 15; 10(2):794-801. PubMed ID: 14760103
    [Abstract] [Full Text] [Related]

  • 18. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
    Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R.
    Mol Cancer Ther; 2003 Apr 15; 2(4):345-51. PubMed ID: 12700278
    [Abstract] [Full Text] [Related]

  • 19. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
    Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C.
    Int J Radiat Oncol Biol Phys; 2003 Mar 01; 55(3):713-23. PubMed ID: 12573759
    [Abstract] [Full Text] [Related]

  • 20. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
    Wang Z, Goulet R, Stanton KJ, Sadaria M, Nakshatri H.
    Anticancer Res; 2005 Mar 01; 25(3c):2367-79. PubMed ID: 16080463
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.